Science and Innovation

New Hope for Triple-Negative Breast Cancer Patients

Triple-negative breast cancer (TNBC) is aggressive, fast growing and spreading, and accounts for about 15-20% of all breast cancer cases. The term “triple-negative breast cancer” denotes the absence of estrogen and progesterone receptors (ER or PR) and the overexpression of the protein HER2. This means typical treatments, such as hormone therapy, are not effective for TNBC patients, making the cancer more difficult to treat.

The tragic outcome is low survival rates.

Combating Cancer Drug Resistance

Y-box binding protein-1 (YB-1) is a widely recognized pro-oncogenic protein classified as a member of the superfamily of highly conserved cold-shock proteins. The overexpression of YB-1 has been linked to tumor progression, cell invasion, and treatment resistance in multiple types of cancer.

YB-1 plays a pivotal role in the development and progression of TNBC.

Read more about the groundbreaking drug discovery and potential to save the lives of triple-negative breast cancer patients in Cell Reports Medicine.